What Клион-Д 100 Treats: Main Uses and Benefits

Клион-Д 100 is applied in clinical settings that involve mixed vaginal infections—conditions where symptoms are caused by both susceptible fungi (like Candida) and protozoa or anaerobic bacteria (linked to trichomoniasis or bacterial vaginosis). This preparation is commonly used across conditions presenting with acute episodes.

The medication is relevant for managing symptoms that interfere with daily comfort, including intense vulvovaginal itching and burning, general soreness, and the presence of abnormal, disruptive discharge. The primary therapeutic benefit provides support that helps ease the overall symptom burden in situations involving certain distressing symptoms. This symptomatic relief helps patients cope more steadily with difficult episodes and supports improved day-to-day comfort during symptomatic periods.

It is applied when appropriate during phases of increased distress or discomfort, particularly in recurrent or episodic manifestations.

“The combination approach is generally applied in scenarios where dual symptomatic management is required.”

Quick Fact: Context for Vulvovaginal Irritation

The dual-action preparation assists with maintaining functional stability and helps with symptom management in acute and recurrent cases.

Regulatory References

1. Official Product Information for Miconazole/Metronidazole

Who Can and Cannot Use Клион-Д 100?

This section outlines the officially documented population eligibility and non-eligibility for Клион-Д 100 based strictly on governmental regulatory information. Eligibility is primarily limited to adult women requiring local treatment.

---

Contraindications and Restrictions

Status	Population/Condition
Absolute Contraindication	Hypersensitivity to Metronidazole, Miconazole, or excipients.
	First Trimester of Pregnancy and Severe Liver Function Disorders (including Porphyria).
	History of blood dyscrasias or diseases of the nervous system.
	Concurrent use of alcohol (during treatment and for 3 days after) or disulfiram.
Not Recommended	Children/Adolescents and Virgins (use not established or advised).
	Breastfeeding mothers (must discontinue breastfeeding for 24–48 hours post-treatment).
Conditional Use	Second and Third Trimesters of Pregnancy (only if essential and under medical observation).
	Patients with severe hepatic or renal impairment (requires caution and potential dose adjustment).

Regulatory documents also state that use is generally not recommended during menstruation and must be avoided concurrently with contraceptive diaphragms or condoms.

Interactions with Other Medicines and Products

The interaction profile of this medicine is primarily defined by the systemic absorption of its Metronidazole and Miconazole components, leading to specific restrictions documented in regulatory labeling.

Contraindicated Combinations and Timing Rules

Co-administration with Disulfiram is formally contraindicated due to the risk of psychotic reactions; a two-week separation from Disulfiram must be observed. The consumption of alcohol or products containing propylene glycol is also contraindicated during treatment and for a period of at least three days following the final dose, due to the risk of a disulfiram-like reaction (flushing, vomiting).

Pharmacokinetic and Exposure Alterations

Both active ingredients are documented inhibitors of Cytochrome P450 enzymes. This metabolic inhibition may lead to increased plasma concentrations of co-administered drugs. This applies notably to Oral Anticoagulants (e.g., Warfarin), where regulatory information notes an enhanced anticoagulant effect and prolongation of prothrombin time. Co-administration with Lithium has been reported to cause elevated plasma lithium concentrations, increasing the risk of toxicity. Similarly, Phenytoin and Carbamazepine may experience an increase in blood concentration. Concomitant use with Busulfan is also documented to increase its serum concentration.

Other Documented Interactions

The excipients in the vaginal tablet base may potentially interact with and damage latex barrier contraceptives, such as condoms and diaphragms, which requires avoidance during treatment.

How Клион-Д 100 Works: The Dual Antimicrobial Mechanism

The action of Клион-Д 100 is defined by the two independent and complementary pharmacodynamic mechanisms of its active ingredients, Metronidazole and Miconazole Nitrate.

Metronidazole: Selective DNA Disruption in Anaerobes The Metronidazole component is a prodrug selectively activated by ferredoxin-linked enzymes found only in anaerobic organisms (bacteria and protozoa like Trichomonas). This reductive activation creates highly cytotoxic nitroso radicals that directly attack and cause strand breakage in the pathogen's DNA. This profound damage causes the loss of viability in susceptible pathogen cells, which results in the physiological resolution of the pathogen-mediated imbalance.

Miconazole: Fungal Membrane Synthesis Inhibition Miconazole Nitrate utilizes a dual mechanism against fungi (Candida species). Its primary action is the inhibition of 14alpha -sterol demethylase, an enzyme necessary for synthesizing ergosterol, which is vital for fungal membrane stability. The resulting lack of ergosterol causes membrane failure. A secondary mechanism involves inhibiting fungal catalase, leading to a buildup of toxic reactive oxygen species (ROS) that inflict internal oxidative damage, leading to the elimination of the fungal population.

This coordinated action results in the cellular death of the two major pathogen classes concurrently, supporting the restoration of the physiological microenvironment following pathogen elimination.

Official Administration Guidelines

Клион-Д 100 (Metronidazole 100 mg / Miconazole Nitrate 100 mg vaginal tablets) must be used according to the established procedures. All instructions pertain solely to the intravaginal route of administration.

---

Dosing Schedule and Application

Feature	Guideline
Route of Administration	Strictly Intravaginal use only.
Standard Dosing	One (1) vaginal tablet per application.
Frequency and Timing	Once daily, applied in the evening just before going to bed.
Course Duration	A full course of treatment is typically 10 consecutive days.

---

Procedural Requirements

To ensure proper application, the following steps are required:

• Preparation: The vaginal tablet must be slightly moistened with water immediately prior to insertion.
• Insertion: The tablet should be inserted deeply into the vagina to ensure correct placement.
• Recurrence Protocol: The initial 10-day course may be repeated if treatment for trichomoniasis is deemed ineffective after clinical assessment.

---

Contextual Conditions

• Concomitant Therapy: When used for trichomoniasis, the local vaginal application is often prescribed alongside a systemic course of oral metronidazole.
• Partner Treatment: For the management of trichomoniasis, the patient's male sexual partner must be treated concurrently with an appropriate oral regimen to avoid re-infection.

Research Evidence / Overview of Studies for Клион-Д 100

Evidence for Use in Mixed Vaginal Infections

Research for this combination product includes short-term Phase III clinical trials and randomized controlled studies. These studies primarily enrolled adult women who had been diagnosed with mixed vaginal infections, which are conditions characterized by fluctuating or episodic manifestations involving both fungal and bacterial or protozoal pathogens. Researchers examined both objective outcomes, such as the potential clearance of multiple organisms and outcomes related to physical discomfort.

Studies monitored how outcomes related to physical discomfort and functional imbalance evolved in the observed populations during the short-term study intervention period. Findings describe patterns observed in the studies related to the measured changes in the number of identified pathogens and corresponding changes measured in outcomes related to symptom intensity. However, long-term outcomes regarding the sustained resolution of these infections are not well characterized.

Evidence Focused on the Antifungal Component (Miconazole Nitrate)

Research has explored the product's role in addressing Vulvovaginal Candidiasis, which is a condition involving periods of heightened symptoms. Researchers monitored microbiological measures (like Candida culture results) and clinical outcomes related to patient-reported physical discomfort (such as itching and burning). Studies report that outcomes related to the measured changes in the number of Candida species were observed in the studied populations.

It remains uncertain how this specific combination product is evaluated directly against Miconazole monotherapy or other local antifungal treatments, as comparative evidence is lacking in head-to-head randomized trials. Data for certain groups, such as those with non-albicans fungal species, remain insufficient.

Evidence Focused on the Anti-protozoal/Anti-bacterial Component (Metronidazole)

The product was studied for its use in conditions like Bacterial Vaginosis (BV) and Trichomonas vaginalis infection. Research examined the Metronidazole component through short-term Randomized Controlled Trials (RCTs). These studies monitored microbiological markers (like changes in Nugent scores for BV) and patient-reported outcomes describing changes in discharge and odor. For Bacterial Vaginosis, some studies described patterns of measured short-term changes in microbiological markers when evaluated against standard oral Metronidazole. For Trichomonas vaginalis infection, pilot studies described patterns of short-term changes in T. vaginalis detection.

What Remains Uncertain About Клион-Д 100 Research

The overall evidence quality varies across studies, and some key limitations persist in the research landscape. Comparative evidence is lacking, especially in direct, head-to-head trials against single-agent monotherapies for the individual components. Data are still emerging for long-term recurrence patterns, and certainty remains low for sustained effects beyond the short-term follow-up periods reported in the major trials. Furthermore, subgroup findings are uncertain for special populations, including older adults or those with specific underlying health conditions.

Key Studies & References

1. Official Product Information for Miconazole/Metronidazole Combination Vaginal Tablet (NAFDAC)
2. The efficacy of a fixed combination of metronidazole and miconazole in the treatment of complicated vaginitis

Common questions about Viberzi (FAQ)

Q: Can I drink alcohol while taking Viberzi?

A: Official regulatory information states that Viberzi (eluxadoline) is contraindicated (must not be used) in patients with alcoholism, alcohol abuse, or those who drink more than three alcoholic beverages per day. This is because these individuals have an increased risk for a serious condition called acute pancreatitis. The prescribing information emphasizes the importance of avoiding chronic or acute excessive alcohol use while the medication is being taken.

Q: What are the most common side effects?

A: According to the official product information and clinical trials, the most frequently reported side effects, occurring in more than 5% of patients, were constipation, nausea, and abdominal pain.

Q: Does Viberzi make you sleepy or affect my ability to drive?

A: Regulatory documents indicate that some reported adverse reactions, such as dizziness and the potential for somnolence (sleepiness) and sedation, may affect mental and physical abilities. The labeling information indicates that patients should be aware that these effects may impair the ability to perform potentially hazardous activities, such as driving a car or operating machinery.

Q: Is it safe to take this drug for a long time?

A: Studies and official information suggest that if a patient does not respond adequately to treatment with Viberzi after four weeks, the medication is often recommended for discontinuation. The official labeling may not specify a maximum duration for all patients who respond well, but an inadequate response warrants stopping treatment.

Q: Can children under 18 years old use this medication?

A: The official product information, including sections on pediatric use, clearly states that the safety and effectiveness in children and adolescents have not been established. For this reason, the medication is generally not recommended for use in patients under 18 years of age.

Q: What if I forget to take a dose?

A: Patient information derived from regulatory sources generally indicates that if a dose of Viberzi is missed, the patient should skip that missed dose entirely. The recommended approach is to continue the regular dosing schedule with the next scheduled dose and avoid taking a double dose to compensate for the missed one.

Q: What happens if I get severe constipation while taking it?

A: Official labeling, including sections on warnings and precautions, advises that if a patient develops severe constipation while on this medication, the treatment is advised to be stopped. Contacting a healthcare provider immediately for guidance is advised in this situation.

How to Store and Dispose of Klion-D 100

Klion-D 100 vaginal tablets must be stored according to specific conditions to maintain their stability and effectiveness, as defined in official regulatory labeling.

---

Official Storage Requirements

Storage Constraint	Required Condition
Temperature	Store at a temperature below 30 C
Environment	Keep in a dry place and protected from light
Packaging	Must be kept in its original package
Safety	Store out of the reach and sight of children

---

Disposal

Any unused or expired Klion-D 100, including waste materials, must be disposed of in accordance with local requirements for medicinal products. This procedure is established by public health authorities to prevent improper environmental disposal.